• In February 2026, Viridian Therapeutics reported fourth-quarter and full-year 2025 results showing modest revenue of US$132,000 for the quarter and US$70.85 million for the year, alongside higher net losses, while also filing a US$16.33 million common stock shelf registration tied to an ESOP-related offering and presenting at a major healthcare conference.
• Beyond the financials, investor attention centers on Viridian’s progress toward potential FDA approval and commercial launch preparations for veligrotug in thyroid eye disease, supported by upcoming clinical data for elegrobart.
• We’ll now examine how Viridian’s progress toward potential FDA approval for veligrotug shapes the company’s investment narrative and risk profile.

Find 49 companies with promising cash flow potential yet trading below their fair value.

What Is Viridian Therapeutics' Investment Narrative?

For Viridian, the core belief is that veligrotug can become a meaningful therapy in thyroid eye disease, with elegrobart potentially extending that franchise if the upcoming REVEAL-1 data are supportive. The latest results underline the trade-off investors are already living with: minimal Q4 revenue of just US$132,000 against a much larger quarterly net loss of US$120.36 million, and a full-year loss of US$342.6 million despite the earlier revenue step-up. The new US$16.33 million ESOP-related shelf looks modest beside those losses and is unlikely to move the near term story as much as the June 30 PDUFA and mid 2026 launch preparations for veligrotug. Instead, it quietly reinforces the existing risk profile of high cash burn, potential dilution and heavy reliance on regulatory success.

However, investors should be aware of how sustained losses and future funding needs could affect them. Despite retreating, Viridian Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Three fair value views from the Simply Wall St Community span from well under US$1 to about US$168, reflecting sharply different expectations just as veligrotug’s FDA decision and Viridian’s rising losses intensify the stakes for future performance and financing.

Explore 3 other fair value estimates on Viridian Therapeutics - why the stock might be worth over 5x more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viridian Therapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viridian Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viridian Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.